Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMNMNASDAQ:MORNASDAQ:MTSRNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$9.36+3.3%$7.69$5.15▼$16.81$814.43M2913,524 shs155,962 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AMTSRMetsera$28.55+1.5%$22.88$12.30▼$32.81$3.00BN/A873,732 shs85,945 shsSRRKScholar Rock$29.55-0.7%$30.33$6.76▼$46.98$2.81B0.371.26 million shs80,412 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome+2.26%+6.71%+2.37%+0.89%-39.36%MORMorphoSys0.00%0.00%0.00%0.00%+3.10%MTSRMetsera+6.07%+3.00%+9.63%+2.29%+2,811,999,900.00%SRRKScholar Rock+2.16%-0.80%-9.57%-19.76%+216.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMNMImmunome2.9305 of 5 stars4.52.00.00.02.12.50.0MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ASRRKScholar Rock4.3385 of 5 stars3.52.00.04.43.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMNMImmunome 3.00Buy$23.33149.29% UpsideMORMorphoSys 0.00N/AN/AN/AMTSRMetsera 3.00Buy$47.0064.62% UpsideSRRKScholar Rock 3.00Buy$42.6744.39% UpsideCurrent Analyst Ratings BreakdownLatest IMNM, MTSR, MOR, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.003/17/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/11/2025IMNMImmunomeLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.003/10/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMNMImmunome$10.94M74.46N/AN/A$2.77 per share3.38MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17MTSRMetseraN/AN/AN/AN/AN/AN/ASRRKScholar Rock$33.19M84.53N/AN/A$3.12 per share9.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMNMImmunome-$106.81M-$3.18N/AN/AN/A-3,014.59%-48.63%-41.62%8/11/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AMTSRMetseraN/AN/A0.00∞N/AN/AN/AN/AN/ASRRKScholar Rock-$165.79M-$2.53N/AN/AN/AN/A-145.60%-91.83%8/14/2025 (Estimated)Latest IMNM, MTSR, MOR, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/A3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMNMImmunomeN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMNMImmunomeN/A6.176.17MORMorphoSys4.981.381.38MTSRMetseraN/AN/AN/ASRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMNMImmunome44.58%MORMorphoSys18.38%MTSRMetseraN/ASRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipIMNMImmunome8.60%MORMorphoSys0.05%MTSRMetseraN/ASRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMNMImmunome4087.01 million72.92 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableMTSRMetsera81105.06 millionN/AN/ASRRKScholar Rock14094.95 million75.64 millionOptionableIMNM, MTSR, MOR, and SRRK HeadlinesRecent News About These CompaniesScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 3 at 3:57 AM | marketbeat.comScholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General ManagerJune 2 at 7:26 PM | uk.finance.yahoo.com20,188 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Acquired by Squarepoint Ops LLCJune 2 at 4:07 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Michael Gilman Sells 3,375 SharesMay 31 at 5:43 PM | marketbeat.comJoshua Reed Sells 5,400 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) StockMay 31 at 5:43 PM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Kristina Burow Sells 5,400 SharesMay 31 at 5:43 PM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 6,075 SharesMay 31 at 5:32 PM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells $200,610.00 in StockMay 31 at 5:32 PM | marketbeat.comInsider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells 3,375 Shares of StockMay 31 at 9:07 AM | insidertrades.comScholar Rock (NASDAQ:SRRK) Shares Down 6.2% - What's Next?May 30, 2025 | marketbeat.comWellington Management Group LLP Has $74.58 Million Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 30, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Receives $42.67 Average Target Price from BrokeragesMay 30, 2025 | americanbankingnews.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Polar Asset Management Partners Inc.May 29, 2025 | marketbeat.comMillennium Management LLC Sells 524,642 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 29, 2025 | marketbeat.comScholar Rock to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | businesswire.comNuveen Asset Management LLC Buys 122,638 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 28, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Given Average Rating of "Buy" by BrokeragesMay 28, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Voloridge Investment Management LLCMay 27, 2025 | marketbeat.comBank of America Corp DE Trims Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 27, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 330,600 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 25, 2025 | marketbeat.comTwo Sigma Investments LP Sells 221,365 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%Best Value Stocks According to Morningstar in 2025By Gabriel Osorio-Mazilli | May 19, 2025View Best Value Stocks According to Morningstar in 2025Trump Orders Nuclear Overhaul: These 3 Stocks Stand to BenefitBy Dan Schmidt | May 28, 2025View Trump Orders Nuclear Overhaul: These 3 Stocks Stand to BenefitIMNM, MTSR, MOR, and SRRK Company DescriptionsImmunome NASDAQ:IMNM$9.36 +0.30 (+3.31%) As of 10:34 AM EasternImmunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 05/30/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Metsera NASDAQ:MTSR$28.55 +0.43 (+1.53%) As of 10:33 AM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Scholar Rock NASDAQ:SRRK$29.55 -0.21 (-0.71%) As of 10:33 AM EasternScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
